Immunobiology of Cancer Metastasis

作者: Jerald J. Killion , Isaiah J. Fidler

DOI: 10.1007/978-1-4471-0201-4_13

关键词:

摘要: Once a diagnosis of cancer is established, the urgent question whether it localized or has already spread to regional lymph nodes and visceral organs. Despite improvements in early diagnosis, surgical techniques, general patient care local systemic adjuvant therapies, most deaths patients result from relentless growth metastatic disease that resistant conventional therapies. Surgical excision primary neoplasms not curative many because by time metastasis may well have occurred. The major challenge for treatment biological heterogeneity cells within lesions especially metastases. A wide range genetic, biochemical, immunological characteristics differ subpopulation include display cell-surface receptors, enzymes, karyotypes, cell morphologies, properties, sensitivities various therapeutic agents ability invade produce [1,2]. This due differences etiology, origin selection pressures. outcome process depends on interaction with host homeostatic factors, which elements immune system. establishment progressive requires they exploit, subvert suppress, when necessary, natural defense systems. chapter will focus host-tumor interactions modulation tumor populations.

参考文章(91)
René Bernards, Suppression of MHC gene expression in cancer cells Trends in Genetics. ,vol. 3, pp. 298- 301 ,(1987) , 10.1016/0168-9525(87)90272-1
Peter J. Wettstein, Donald W. Bailey, Immunodominance in the immune response to "multiple" histocompatibility antigens. Immunogenetics. ,vol. 16, pp. 47- 58 ,(1982) , 10.1007/BF00364441
C F Nathan, Secretory products of macrophages. Journal of Clinical Investigation. ,vol. 79, pp. 319- 326 ,(1987) , 10.1172/JCI112815
S. Ostrand-Rosenberg, S. Baskar, N. Patterson, V. K. ClementsDepartment of Biologi Sciences, Expression of MHC Class II and B7–1 and B7–2 costimulatory molecules accompanies tumor rejection and reduces the metastatic potential of tumor cells Tissue Antigens. ,vol. 47, pp. 414- 421 ,(1996) , 10.1111/J.1399-0039.1996.TB02577.X
Jason D. Lickliter, Robert A. Kratzke, Phuong L. Nguyen, Gloria A. Niehans, Jeffrey S. Miller, Fas ligand is highly expressed in acute leukemia and during the transformation of chronic myeloid leukemia to blast crisis Experimental Hematology. ,vol. 27, pp. 1519- 1527 ,(1999) , 10.1016/S0301-472X(99)00091-0
A. Lindemann, F. Herrmann, W. Oster, R. Mertelsmann, Lymphokine activated killer cells. Annals of Hematology. ,vol. 59, pp. 375- 384 ,(1989) , 10.1007/BF00321208
B. Passlick, K. Pantel, B. Kubuschok, M. Angstwurm, A. Neher, O. Thetter, L. Schweiberer, J.R. Izbicki, Expression of MHC molecules and ICAM-1 on non-small cell lung carcinomas: Association with early lymphatic spread of tumour cells European Journal of Cancer. ,vol. 32, pp. 141- 145 ,(1996) , 10.1016/0959-8049(95)00551-X
Patrick Terheyden, Claudia Siedel, Angela Merkel, Eckhart Kämpgen, Eva-B Bröcker, Jürgen C. Becker, Predominant Expression of Fas (CD95) Ligand in Metastatic Melanoma Revealed by Longitudinal Analysis Journal of Investigative Dermatology. ,vol. 112, pp. 899- 902 ,(1999) , 10.1046/J.1523-1747.1999.00607.X
George Poste, Isaiah J. Fidler, The pathogenesis of cancer metastasis Nature. ,vol. 283, pp. 139- 146 ,(1980) , 10.1038/283139A0